secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0000950170-25-040758
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics CEO Kaye steps down; Ian Smith named interim; FY 2024 net loss $89M
--------------------------------------------------------------------------------

- CEO Edward Kaye steps down March 19; Ian F. Smith appointed Interim CEO; Arthur Tzianabos named Interim Executive Chair.
- Full year 2024 net loss $89.0M ($1.65/share) vs $104.7M loss in 2023; revenue $36.6M from Acadia collaboration (vs $8.8M prior year).
- Cash, equivalents, and marketable securities $246.7M at Dec 31, 2024; plus $165M upfront from Biogen collaboration funds operations to mid-2028.
- Phase 3 registrational study (EMPEROR) of zorevunersen for Dravet syndrome on track to initiate in Q2 2025.
- Board initiates search for permanent CEO; Kaye remains as advisor and director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000095017025040758/0000950170-25-040758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000095017025040758/stok-20250318.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer